Katie R. Pang

Baylor College of Medicine, Houston, Texas, United States

Are you Katie R. Pang?

Claim your profile

Publications (25)52.87 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the most common malignancy in men in the United States. However, skin metastasis from prostate carcinoma is extremely uncommon. Here, we present a 75-year-old Caucasian man with a history of metastatic prostate cancer developing multiple subcutaneous, erythematous nodules over the left anterior chest over a 3-month period. A fine needle aspiration of a subcutaneous nodule showed neoplastic cells consistent with metastatic prostate cancer. This case represents only the fourth reported case of cutaneous metastasis from prostate cancer to the chest wall and the ninth case outside the inguinal area.
    International Journal of Dermatology 09/2006; 45(8):946-8. DOI:10.1111/j.1365-4632.2004.02503.x · 1.23 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects. However, it has since made a remarkable comeback for the U.S. Food and Drug Administration-approved use in the treatment of erythema nodosum leprosum. Further, it has shown its effectiveness in unresponsive dermatological conditions such as actinic prurigo, adult Langerhans cell histiocytosis, aphthous stomatitis, Behçet's syndrome, graft-versus-host disease, cutaneous sarcoidosis, erythema multiforme, Jessner-Kanof lymphocytic infiltration of the skin, Kaposi sarcoma, lichen planus, lupus erythematosus, melanoma, prurigo nodularis, pyoderma gangrenosum and uraemic pruritus. This article reviews the history, pharmacology, mechanism of action, clinical uses and adverse effects of thalidomide.
    British Journal of Dermatology 09/2005; 153(2):254-73. DOI:10.1111/j.1365-2133.2005.06747.x · 4.10 Impact Factor
  • Journal of Cutaneous Maedicine and Surgery 07/2005; 9(3):105-15. DOI:10.1007/s10227-005-0134-z · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The rickettsial diseases are an important group of infectious agents that have dermatological manifestations. These diseases are important to consider in endemic areas, but in certain suspicious cases, possible acts of bioterrorism should warrant prompt notification of the appropriate authorities. In this two part review article, we review these diverse diseases by examining established and up-to-date information about the pathophysiology, epidemiology, clinical manifestations, and treatment of the ricksettsiae. Using PubMed to search for relevant articles, we browsed over 500 articles to compose a clinically based review article. Part one focuses on pathophysiology of the rickettsial diseases and the clinical aspects of the spotted fever group. At the completion of part one of this learning activity, participants should be able to discuss all of the clinical manifestations and treatments of the sported fever group. Participants should also be familiar with the pathophysiology of the rickettsial diseases.
    Journal of Cutaneous Maedicine and Surgery 05/2005; 9(2):54-62. DOI:10.1007/s10227-005-0133-0 · 0.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Infections with five of the herpesviruses (herpes simplex virus 1 [HSV-1], HSV-2, varicella zoster virus, Epstein-Barr virus, and cytomegalovirus) are treated with topical or systemic antiviral therapies. There are more than 100 genotypes of human papillomaviruses (HPVs), which may manifest as warts, skin cancers, cervical cancer, anogenital cancers, and upper digestive tract cancers. Molluscum contagiosum (MC) is a common, benign viral infection of the skin. Immunomodulating agents, such as imiquimod, act on HPV and MC indirectly by inducing host immune responses, such as cytokines and cell-mediated immunity, and thereby reduce recurrences. There are multiple vaccines available for certain viral diseases and others in development for HSV-2 and HPV.
    Dermatologic Clinics 05/2005; 23(2):313-22. DOI:10.1016/j.det.2004.09.001 · 1.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The cytokine family of interferons (IFNs) has multiple functions, including antiviral, anti-tumor, and immunomodulatory effects and regulation of cell differentiation. The multiple functions of the IFN system are thought to be an innate defense against microbes and foreign substances. The IFN system consists first of cells that produce IFNs in response to viral infection or other foreign stimuli and second of cells that establish the antiviral state in response to IFNs. This process of innate immunity involves multiple signaling mechanisms and activation of various host genes. Viruses have evolved to develop mechanisms that circumvent this system. IFNs have also been used clinically in the treatment of viral diseases. Improved treatments will be possible with better understanding of the IFN system and its interactions with viral factors. In addition, IFNs have direct and indirect effects on tumor cell proliferation, effector leukocytes and on apoptosis and have been used in the treatment of some cancers. Improved knowledge of how IFNs affect tumors and the mechanism that lead to a lack of response to IFNs would help the development of better IFN treatments for malignancies.
    Methods in molecular medicine 02/2005; 116:1-23. DOI:10.1385/1-59259-939-7:1
  • [Show abstract] [Hide abstract]
    ABSTRACT: There are eight members of the herpesviridae family: herpes simplex virus-1 (HSV-1), HSV-2, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus, human herpes virus-6, human herpes virus-7 and human herpes virus-8. The diseases caused by viruses of the herpesviridae family are treated with and managed by systemic and topical antiviral therapies and immunomodulating drugs. Because these viruses establish a latent state in hosts, antiherpetic agents, such as nucleoside analogues, only control symptoms of disease or prevent outbreaks, and cannot cure the infections. There is a need for treatments that require less frequent dosing, can be taken even when lesions are more advanced than the first signs or symptoms, and can treat resistant strains of the viruses without the toxicities of existing therapies. Immunomodulating agents, such as resiquimod, can act on the viruses indirectly by inducing host production of cytokines, and can thereby reduce recurrences of herpes. The new helicase primase inhibitors, which are the first non-nucleoside antiviral compounds, are being investigated for treatment of HSV disease, including infections resistant to existing therapy.
    Expert Opinion on Emerging Drugs 12/2004; 9(2):237-56. DOI:10.1517/14728214.9.2.237 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although sexually transmitted diseases (STDs) are underreported and underrecognized, they are a major source of morbidity, mortality, and represent a major socioeconomic cost in developing and industrialized nations. Individuals who develop STDs are often coinfected with human immunodeficiency virus (HIV). Coinfection with HIV both facilitates the natural history of STDs and worsens the clinical picture. The objective of this article is to provide a review to the practicing clinician on the epidemiology, clinical manifestations, methods of diagnosis, and treatment for four cutaneous STDs--chancroid, genital herpes, granuloma inguinale, and lymphogranuloma venereum--in coinfected HIV patients.
    Clinics in Dermatology 11/2004; 22(6):499-508. DOI:10.1016/j.clindermatol.2004.07.008 · 1.93 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Although the development of antimicrobial drugs has advanced rapidly in the past several years, such agents act against only certain groups of microbes and are associated with increasing rates of resistance. These limitations of treatment force physicians to continue to rely on prevention, which is more effective and cost-effective than therapy. From the use of the smallpox vaccine by Jenner in the 1700s to the current concerns about biologic warfare, the technology for vaccine development has seen numerous advances. The currently available vaccines for viral illnesses include Dryvax for smallpox; the combination measles, mumps, and rubella vaccine; inactivated vaccine for hepatitis A; plasma-derived vaccine for hepatitis B; and the live attenuated Oka strain vaccine for varicella zoster. Vaccines available against bacterial illnesses include those for anthrax, Haemophilus influenzae, and Neisseria meningitidis. Currently in development for both prophylactic and therapeutic purposes are vaccines for HIV, herpes simplex virus, and human papillomavirus. Other vaccines being investigated for prevention are those for cytomegalovirus, respiratory syncytial virus, parainfluenza virus, hepatitis C, and dengue fever, among many others. Fungal and protozoan diseases are also subjects of vaccine research. Among immunoglobulins approved for prophylactic and therapeutic use are those against cytomegalovirus, hepatitis A and B, measles, rabies, and tetanus. With this progress, it is hoped that effective vaccines soon will be developed for many more infectious diseases with cutaneous manifestations.
    Journal of the American Academy of Dermatology 05/2004; 50(4):495-528; quiz 529-32. DOI:10.1016/j.jaad.2003.12.003 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.358 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.361 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.655 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.138 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.187 · 5.00 Impact Factor
  • Journal of the American Academy of Dermatology 03/2004; 50(3). DOI:10.1016/j.jaad.2003.10.337 · 5.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The incidence of both community-acquired and nosocomial fungal infections has significantly increased over the past several decades. The major factors for this increase are a heightened use of antibiotics, a growing population of the elderly and of immunocompromised patients as a result of HIV, cancer, and organ transplantation. In this article, we will review the indications, efficacy, and safety of the polyenes, imidazoles, triazoles, and other systemic antifungals in development that are used for systemic fungal infections.
    Dermatologic Therapy 02/2004; 17(6):532-8. DOI:10.1111/j.1396-0296.2004.04057.x · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Subcutaneous mycoses are caused by a variety of mostly tropical organisms, usually when they are implanted into the dermis or the subcutaneous tissue. They rarely disseminate or become systemic. Sporotrichosis, mycetoma, and chromoblastomycosis are more common subcutaneous mycoses than are rhinosporidiosis, zygomycosis, pheohyphomycosis, and lobomycosis.
    Dermatologic Therapy 02/2004; 17(6):523-31. DOI:10.1111/j.1396-0296.2004.04056.x · 1.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Superficial fungal infections are common, especially onychomycosis, dermatophytoses, and superficial Candida infections. Most superficial fungal infections are treated with topical antifungal agents unless the infection covers an extensive area or is resistant to initial therapy. Onychomycosis often requires systemic therapy with griseofulvin, itraconazole, or terbinafine. The objective of this review is to provide the practicing dermatologist with the recommended available therapy for the treatment of common superficial fungal infections.
    Dermatologic Therapy 02/2004; 17(6):517-22. DOI:10.1111/j.1396-0296.2004.04055.x · 1.48 Impact Factor